95 patents
Utility
Methods and Compositions for Treating, Preventing, Inhibiting, Ameliorating or Delaying the Onset of Ophthalmic Conditions
21 Dec 23
The disclosure generally relates to compounds (i.e. peptidomimetics), compositions (e.g. formulations or medicaments), methods and related uses for treating, preventing, inhibiting, amelioration or delaying the onset of ophthalmic diseases, disorders or conditions in a mammalian subject, such as a human.
Dennis Keefe, Martin Redmon, Brian Hotchkiss, Anthony Abbruscato
Filed: 1 Sep 23
Utility
Methods and Compositions for Preventing or Treating Ophthalmic Conditions
30 Nov 23
The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy.
Liping Liu, Shibo Tang, Xiaoling Liang
Filed: 11 Aug 23
Utility
Methods and Compositions for Preventing or Treating Ophthalmic Conditions
2 Nov 23
The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy.
Liping Liu, Shibo Tang, Xiaoling Liang
Filed: 9 Feb 23
Utility
Mitochondria-targeting peptides
24 Oct 23
Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.
Guozhu Zheng, Mark J. Bamberger, Inese Smukste
Filed: 14 Dec 18
Utility
Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH
3 Oct 23
Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.
Scott M. Duncan
Filed: 8 Apr 21
Utility
Methods and compositions for the prevention or treatment of Barth syndrome
3 Oct 23
The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome.
D. Travis Wilson, Mark Bamberger
Filed: 9 Jul 21
Utility
Compositions and Methods for the Prevention And/or Treatment of Mitochondrial Disease, Including Friedreich's Ataxia
28 Sep 23
The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia.
Dennis Keefe, Guozhu Zheng, Pavels Arsenjans
Filed: 23 Dec 22
Utility
Methods for the Treatment of Mitochondrial Disease
7 Sep 23
The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof.
D. Travis Wilson
Filed: 11 Oct 22
Utility
Prodrugs of Mitochondria-targeting Oligopeptides
7 Sep 23
Disclosed are various prodrugs of L-Phe-D-Arg-L-Phe-L-Lys-NH2.
Guozhu Zheng, Pavels Arsenjans
Filed: 22 Jun 21
Utility
Methods and Compositions for the Treatment of Muscular Dystrophy
17 Aug 23
The disclosure provides methods for treating muscular dystrophy (MD), such as Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) in a mammalian subject.
David BROWN, Jim CARR, Dennis Keefe
Filed: 16 Jun 21
Utility
Prodrugs of Mitochondria-targeting Oligopeptides
20 Jul 23
Disclosed are various prodrugs of Elamipretide.
Guozhu Zheng, Pavels Arsenjans
Filed: 22 Jun 21
Utility
Crystalline Dipeptides Useful In the Synthesis of Elamipretide
29 Jun 23
Disclosed are crystalline forms of L-Lys(Boc)-Phe-NH2 and Boc-D-Arg-DMT.
Scott M. Duncan, Martin P. Redmon
Filed: 21 Dec 22
Utility
Mitochondria-targeting Peptides
11 May 23
Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.
Guozhu Zheng, Mark J. Bamberger, Inese Smukste
Filed: 14 Dec 18
Utility
Methods and Compositions for the Prevention and Treatment of Duchenne Muscular Dystrophy
6 Apr 23
The disclosure provides methods of preventing or treating DMD in a mammalian subject, reducing risk factors associated with DMD, and/or reducing the likelihood or severity of DMD.
D. Travis Wilson
Filed: 3 May 22
Utility
Methods and compositions for preventing or treating ophthalmic conditions
28 Mar 23
The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy.
Liping Liu, Shibo Tang, Xiaoling Liang
Filed: 2 Jul 20
Utility
Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
21 Feb 23
The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia.
Dennis Keefe, Guozhu Zheng, Pavels Arsenjans
Filed: 2 Oct 20
Utility
Methods and Compositions for the Prevention and Treatment of Disease
9 Feb 23
The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes.
D. Travis Wilson
Filed: 22 Jun 22
Utility
Methods and Compositions for Detecting and Diagnosing Diseases and Conditions
2 Feb 23
The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling.
D. Travis Wilson
Filed: 30 Mar 22
Utility
Crystalline dipeptides useful in the synthesis of elamipretide
24 Jan 23
Disclosed are crystalline forms of L-Lys(Boc)-Phe-NH2 and Boc-D-Arg-DMT.
Scott M. Duncan, Martin P. Redmon
Filed: 7 Apr 21
Utility
Crystalline salt forms
17 Jan 23
Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.
Scott M. Duncan, Martin P. Redmon
Filed: 4 May 20